Verapamil as an adjunct to LA in usg guided supraclavicular brachial plexus block

comparison of 0.5% bupivacine alone versus 0.5% bupivacaine with verapamil as an adjunct in ultra sound guided supraclavicular brachial plexus block - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062429

Enrollment

120

Registered

2024-02-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: bupivacaine in usg guided brachial plexus block: The study aims to compare verapamil as an adjunct to bupivacaine in terms of onset and duration of sensory and motor block , hemodyanmic

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade 1 and 2 Elective upper limb surgeries Patients of either sex aged 18 to 60 years Total body weight between 45 to 80 kgs

Exclusion criteria

Exclusion criteria: Allergy to bupivacaine and verapamil Pregnant Patient with chest deformity and clavicle fracture Patient with coagulopathies Pateint with pre existing motor and sensory deficiet Active infection at the site of the injection

Design outcomes

Primary

Measure	Time frame
Onset and duration of sensory and motor block , hemodyanmic stabile like heart rate, blood pressure,spo2, time for first rescue analgesia and side effects if anyTimepoint: Outcomes mentioned above will be measured at o mins , 15 mins, 30 mins , 45 mins , 1 hrs , 2 hrs , 4 hrs and finally at 6 hrs of block	—

Secondary

Measure	Time frame
Time taken to perform block under usg guidance, to evaluate block performance and side effects due to technique like pneumothorax, Horner syndrome etcTimepoint: Up to 24hrs	—

Countries

India

Contacts

Public ContactDr Suneeta Dutta

Silchar medical college and hospital

drsuneetadutta@gmail.com9435074110

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026